SHAREHOLDER ALERT: Investors Who Sold Allergan, Inc. Common Stock Between February 25, 2014 and April 21, 2014 Are Encouraged to Contact Glancy Binkow & Goldberg LLP

LOS ANGELES--(BUSINESS WIRE)--

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of persons who sold the common stock of Allergan, Inc. (“Allergan” or the “Company”) AGN between February 25, 2014 and April 21, 2014, concerning possible violations of federal securities laws. Investors who have losses of $100,000 or more are encouraged to contact the firm for more information.

Please contact Casey Sadler or Lesley Portnoy at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

The investigation is related to alleged violations of federal securities laws by Valeant Pharmaceuticals International, Inc. and Pershing Square Capital Management L.P., among others. Specifically, the investigation is related to allegations that Valeant unlawfully tipped Pershing Square about its plan to make a tender offer for Allergan, with Pershing Square then trading on non-public information by buying an approximately 9.7% stake in Allergan without first disclosing Valeant's plan to pursue a tender offer to acquire Allergan at a significant premium.

If you sold shares of Allergan stock between February 25, 2014 and April 21, 2014, and suffered losses of $100,000 or more, or if you would like to learn more about these claims and have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, or Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at (310) 201-9150, Toll Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.